NCT05189704

Brief Summary

This study is a randomized, controlled, double-blinded, and parallel design study. A total 94 patients will be randomized to receive ketorolac or fentanyl based patient-controlled analgesia after microvascular decompression surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
94

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 7, 2021

Completed
13 days until next milestone

Study Start

First participant enrolled

December 20, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

January 12, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2023

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2023

Completed
Last Updated

April 13, 2023

Status Verified

April 1, 2023

Enrollment Period

1.2 years

First QC Date

December 7, 2021

Last Update Submit

April 12, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative nausea and vomiting

    Incidence

    postoperative 48 hours

Secondary Outcomes (7)

  • Postoperative nausea and vomiting

    Postoperative 30 minutes, 1 hours, 24 hours, 48 hours

  • Postoperative pain

    Postoperative 30 minutes, 1 hours, 24 hours, 48 hours

  • Postoperative PCA consumption

    Postoperative 30 minutes, 1 hours, 24 hours, 48 hours

  • Rescue antiemetics requirement

    Postoperative 30 minutes, 1 hours, 24 hours, 48 hours

  • Rescue analgesic requirement

    Postoperative 30 minutes, 1 hours, 24 hours, 48 hours

  • +2 more secondary outcomes

Study Arms (2)

NSAID group

EXPERIMENTAL

NSAID based patient-controlled analgesia will connected to intravenous line for pain control.

Drug: NSAID

Opioid group

ACTIVE COMPARATOR

Opioid based patient-controlled analgesia will connected to intravenous line for pain control.

Drug: Opioid

Interventions

NSAIDDRUG

NSAID based patient-controlled analgesia will connected to intravenous line for pain control.

NSAID group
OpioidDRUG

Opioid based patient-controlled analgesia will connected to intravenous line for pain control.

Opioid group

Eligibility Criteria

Age19 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who undergo elective microvascular decompression surgery
  • American Society of Anesthesiologists grade 1 or 2
  • years old

You may not qualify if:

  • Refuse to participate to the study
  • Refuse to use Patient-controlled analgesia
  • Body Mass Index \< 18.5 kg/m2 or \> 35 kg/m2
  • history of craniotomy or chemotheraphy
  • Patients who used preoperative antiemetics within 24h before surgery
  • Severe renal or hepatic dysfunction
  • Pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea

RECRUITING

MeSH Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

Anti-Inflammatory Agents, Non-SteroidalAnalgesics, Opioid

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNauseaSigns and Symptoms, DigestiveSigns and SymptomsVomiting

Intervention Hierarchy (Ancestors)

Analgesics, Non-NarcoticAnalgesicsSensory System AgentsPeripheral Nervous System AgentsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesAnti-Inflammatory AgentsTherapeutic UsesAntirheumatic AgentsNarcoticsCentral Nervous System DepressantsCentral Nervous System Agents

Study Officials

  • Chang-Hoon Koo

    Seoul National University Bundang Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chang-Hoon Koo

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

December 7, 2021

First Posted

January 12, 2022

Study Start

December 20, 2021

Primary Completion

February 15, 2023

Study Completion

August 31, 2023

Last Updated

April 13, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations